DNA methylation has been widely studied as an epigenetic modification that influences gene regulation and genome stability. The Genomic Core uses the NEBNext Enzymatic Methyl-seq (EM-Seq) method from New England Biolabs to identify 5-methylcytosine and 5-hydroxymethylcytosine sites across the genome. The method has the advantage of minimizing damage to DNA in comparison to the harsher conditions of bisulfite treatment. Therefore, less input DNA is required to sequence.

All sequencing is generated on an Illumina NovaSeq X Plus. The NovaSeq X platform is particularly useful for differential gene expression studies due to the high data yields, multiplexing capabilities, and high data quality. Quality control and quality assurance metrics are incorporated into each standard operating procedure to monitor performance of each service provided.